financetom
Business
financetom
/
Business
/
Boeing Shares Down After LATAM Airlines' 787 Jet Experiences Turbulence
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Boeing Shares Down After LATAM Airlines' 787 Jet Experiences Turbulence
Mar 11, 2024 11:20 AM

01:45 PM EDT, 03/11/2024 (MT Newswires) -- Boeing's ( BA ) shares were down more than 3% in recent Monday trading after LATAM Airlines' Boeing 787 experienced "strong shake," during a flight from Sydney, Australia, to Auckland, New Zealand.

As a result 10 passengers and three cabin crew members were taken to a hospital, after the plane landed at Auckland Airport. The causes of the turbulence are being investigated, LATAM Airlines said.

"We are working to gather more information about the flight and will provide any support needed by our customer," Boeing ( BA ) said in a statement to MT Newswires.

In addition, Delta Air Lines ( DAL ) said Sunday it expects delays in the delivery of Boeing's ( BA ) 737 Max 10 planes until as late as 2027, citing ongoing federal safety and criminal reviews of the aircraft manufacturer, Bloomberg reported.

Neither LATAM Airline nor Delta Air Lines ( DAL ) immediately responded to MT Newswires' requests for comment.

Price: 192.04, Change: -6.45, Percent Change: -3.25

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
BRIEF-RTW Biotech Annonuces Biogen To Acquire Alcyone Therapeutics
BRIEF-RTW Biotech Annonuces Biogen To Acquire Alcyone Therapeutics
Sep 23, 2025
Sept 23 (Reuters) - RTW Biotech Opportunities Ltd ( RTWFF ) : * RTW BIOTECH OPP. - BIOGEN TO ACQUIRE ALCYONE THERAPEUTICS * RTW BIOTECH OPPORTUNITIES LTD ( RTWFF ) - BIOGEN TO PAY $85 MILLION UPFRONT FOR ALCYONE Source text: Further company coverage: ...
AvePoint Insider Sold Shares Worth $3,285,360, According to a Recent SEC Filing
AvePoint Insider Sold Shares Worth $3,285,360, According to a Recent SEC Filing
Sep 23, 2025
03:42 AM EDT, 09/23/2025 (MT Newswires) -- James Caci, Chief Financial Officer, on September 18, 2025, sold 216,000 shares in AvePoint ( AVPT ) for $3,285,360. Following the Form 4 filing with the SEC, Caci has control over a total of 213,030 common shares of the company, with 213,030 shares held directly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1777921/000143774925029637/xslF345X05/rdgdoc.xml ...
AvePoint Insider Sold Shares Worth $31,468,973, According to a Recent SEC Filing
AvePoint Insider Sold Shares Worth $31,468,973, According to a Recent SEC Filing
Sep 23, 2025
03:43 AM EDT, 09/23/2025 (MT Newswires) -- Tianyi Jiang, Director, Chief Executive Officer, on September 18, 2025, sold 2,068,966 shares in AvePoint ( AVPT ) for $31,468,973. Following the Form 4 filing with the SEC, Jiang has control over a total of 13,841,853 common shares of the company, with 13,841,853 controlled indirectly. SEC Filing: https://www.sec.gov/Archives/edgar/data/1777921/000143774925029638/xslF345X05/rdgdoc.xml ...
EXPLAINER-Why is leucovorin being considered as an autism treatment?
EXPLAINER-Why is leucovorin being considered as an autism treatment?
Sep 23, 2025
(Adds detail about GSK in paragraph 3) By Nancy Lapid Sept 23 (Reuters) - On Monday, the U.S. Food and Drug Administration published a notice to the Federal Register ahead of a speech by President Donald Trump, approving a version of leucovorin made by GlaxoSmithKline that the company had previously withdrawn from the FDA's consideration when it stopped manufacturing the...
Copyright 2023-2026 - www.financetom.com All Rights Reserved